A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.
about
T lymphocytes targeting native receptorsAntiviral T-cell therapyVirus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disordersControlling cytomegalovirus: helping the immune system take the leadStrategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodCMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance.Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplantRisk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.T-cell therapies for Epstein-Barr virus-associated lymphomas.T-cell therapy in the treatment of post-transplant lymphoproliferative diseaseRecent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.Umbilical cord blood graft engineering: challenges and opportunities.Antigen-specific T cell therapies for cancer.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.Advances in umbilical cord blood cell therapy: the present and the future.Immunotherapy against cancer-related viruses.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantationManagement of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.Impact of T cell selection methods in the success of clinical adoptive immunotherapy.Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.
P2860
Q26853345-3EF1D354-7C3B-4066-BFF0-455A76B42DADQ27028006-BCFCD708-3610-4941-A7AF-9F60BD5D31ABQ33650689-5FEEBEE7-5C80-496E-9DB5-D813F20788F7Q33820695-E851C7E7-99D9-448B-B1B3-F9F0D79E36A2Q34622755-76C3CE6C-B92A-489A-AE79-B18A2AEC800BQ35582326-C11A8BAD-9E80-45D1-BCF3-ACDCFC9F9F53Q35776868-5C793188-E635-4862-ADDE-518CF0BA9058Q36153492-C40C7DE8-F48D-409E-97E2-D88FDEA0CE9DQ36956443-DB4550A2-224E-4ABC-A430-5527B480C37BQ37058107-1A791A65-F61D-4A77-876C-B01D5B990C12Q37552052-792BEAB2-0AA4-4BD2-8282-D58ECB298ED1Q37592177-E6589002-FE27-4DF6-8645-E9CF8FDE8697Q37948940-3E3D4411-CA21-408F-BB4E-7C12E42A3CEFQ38026758-D3D79197-5E12-4EE7-A7D5-9858D1BD7FBDQ38066586-C944EA1B-38AE-46BD-ACE5-CB693B4E44BEQ38119843-958E8FE1-3393-4689-99FC-E7EFF64F7FCEQ38514503-123016CB-5D92-41C9-A9E0-B7228EA10192Q38544740-1CD41E87-9EE6-414D-8201-0A39E673F7D7Q38640239-A6CDEEFB-3440-4359-8BDE-2A3FDCFF0217Q38734758-6C5B2F6B-023E-4437-918F-E44F8B9AA31DQ38778924-01484A4D-AB91-4ABB-9390-9DF1B9D157DDQ38803361-FAD86F7A-9801-4DB9-8C95-A1AF46ABCD8FQ40730089-73897A09-DC60-4866-BF2A-A6C9D1F1A399Q41623045-B87A7F43-C233-460D-B023-0190B7FC9519Q42265908-A0B0D52E-C21B-4B0D-91A6-8DF8ABECAD22Q42271011-B39C8941-3462-4B3B-81F2-7021B32FBE99Q45356159-64028474-3C2E-4736-8DCC-95F8BFC51CD5Q47603836-308D51FE-FF0A-42F5-B080-4A40E2C0F338
P2860
A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A novel haplo-identical adopti ...... ter stem cell transplantation.
@ast
A novel haplo-identical adopti ...... ter stem cell transplantation.
@en
type
label
A novel haplo-identical adopti ...... ter stem cell transplantation.
@ast
A novel haplo-identical adopti ...... ter stem cell transplantation.
@en
prefLabel
A novel haplo-identical adopti ...... ter stem cell transplantation.
@ast
A novel haplo-identical adopti ...... ter stem cell transplantation.
@en
P2093
P1476
A novel haplo-identical adopti ...... ter stem cell transplantation.
@en
P2093
Jens Gertow
Mantas Okas
Mehmet Uzunel
Michael Uhlin
Torkel B Brismar
P2888
P304
P356
10.1007/S00262-009-0789-1
P577
2009-11-12T00:00:00Z